Medigene participates at upcoming conferences

Planegg – Medigene AG (FSE: MDG1, Prime Standard, SDAX) today announced its participation at the following upcoming scientific conferences:

Date: 24 – 27 February
Location: Munich, Germany

Whistler Conference Centre
Date: 10 – 14 March 2019
Location: Whistler, Canada

Immuno Oncology Summit Europe
Date: 18 – 22 March 2019
Location: London, UK
Dr Slavoljub Milosevic will give a presentation on “Rapid High-Throughput Functional Selection of Neoantigens and Assessment of Their Safety” on 18 March 2019

9th Gene Quantification Event qPCR dPCR & NGS 2019
Symposium & Industrial Exhibition & Application Workshops
Date: 18 – 22 March 2019
Location: Freising-Weihenstephan, Germany

International Cellular Therapy Symposium 2019
Date: 22 – 23 March 2019
Location: Erlangen, Germany
Dr. Daniel Sommermeyer will give a poster presentation on “HA-1-specific T-cell receptors for the treatment of hematological malignancies” on 22 March 2019

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies, with associated projects currently in pre-clinical and clinical development.

For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 – 89 – 20 00 33 – 33 01,